Last quarter, Gilead Sciences (NASDAQ: GILD) forked over $8 billion to buy back 46 million shares of its stock — and despite that massive repurchase, the company still plans on spending billions of dollars more on buybacks this year. Does Gilead Sciences’ commitment to share repurchases suggest management thinks its stock is the best bargain in biotech?